Redeye remains confident on the case although Q2 numbers came in a little shy of our expectations. Adjusted for IP/royalty revenues from the Bosch, sales grew ~12% Y/Y. But we are encouraged by the strong news flow lately where Powercell has signed several important deals with significant future potential. Also, the current order backlog is substantial suggesting a strong H2’25.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/